XING AG

  • WKN: XNG888
  • ISIN: DE000XNG8888
  • Land: Deutschland

Nachricht vom 07.09.2010 | 15:39

XING AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


XING AG / Release of an announcement according to Article 21, Section 1
of the WpHG [the German Securities Trading Act] (share)

07.09.2010 15:39

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

Baillie Gifford Overseas Ltd., Edinburgh, Scotland, has informed us on September 6, 2010 as follows: 1. Baillie Gifford Overseas Limited, Edinburgh, Scotland We hereby give notice, pursuant to sec. 21 para. 1 of the WpHG, that on 3 September 2010 the voting interest of Baillie Gifford Overseas Limited, Edinburgh, Scotland in XING AG exceeded the 3 percent threshold and on this date amounted to 3.10% (this corresponds 163,500 voting rights). All of these voting rights (this corresponds to 163,500 voting rights) are attributed to Baillie Gifford Overseas Limited in accordance with sec. 22 para. 1 sent. 1 no. 6 WpHG. 2. Baillie Gifford & Co, Edinburgh, Scotland We hereby give notice, pursuant to sec. 21 para. 1 of the WpHG, that on 3 September 2010 the voting interest of Baillie Gifford & Co, Edinburgh, Scotland in XING AG exceeded the 3 percent threshold and on this date amounted to 3.10% (this corresponds 163,500 voting rights). All of these voting rights (this corresponds to 163,500 voting rights) are attributed to Baillie Gifford & Co in accordance with sec. 22 para. 1 sent. 1 no. 6 and sent. 2 of the WpHG (via Baillie Gifford Overseas Limited). XING AG, Hamburg, Germany 07.09.2010 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: XING AG Gänsemarkt 43 20354 Hamburg Deutschland Internet: www.xing.com End of Announcement DGAP News-Service

GBC im Fokus

Ergomed PLC: Kursziel angehoben

Die erfolgreiche Wirksamkeitsstudie von Lorediplon zeigt, dass Ergomed PLC eine sehr vielversprechende Co-Development-Pipeline hat. Eine mögliche vorzeitige Auslizenzierungen des Produkts würde dem Unternehmen signifikante Erfolgsbeteiligungen sichern. Deshalb und aufgrund der Anpassung der Wechselkurse erhöhen wir den fairen Wert der Ergomed-Aktie auf 3,41 € je Aktie. Das Rating bleibt KAUFEN.

News im Fokus

Henkel AG & Co. KGaA:

23. Februar 2017, 07:30

Aktueller Webcast

XING AG

Preliminary Results 2016

23. Februar 2017

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

23. Februar 2017